CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C
LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (OTCQB: CYTR) (“CytRx”), a specialized biopharmaceutical company focused on research and…
Akkodis Named a Leader in ISG Provider Lens(TM) Digital Engineering Services 2026 Reports
Sinch Mailgun Report: Companies are Leaving Email Performance on the Table
Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance
GMG Appoints New Chief Production Growth Officer and Provides Update on Global Production Plans
TMX Group Announces Agreement to Acquire Cboe Australia and Cboe Canada